Oxford Biomedica (uk) Limited

Oxford Biomedica, Inc.

Stuart Naylor

Susan Mary Kingsman

Richard Harrop

William Shingler

Nicholas D Mazarakis

Michael McDonald

Patrick Aebischer

Michael Mcdonald

The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising:

Immunotherapeutic method

Disclosed and claimed are methods for treating or preventing neurodegenerative diseases, conditions or maladies or symptoms or physiology associated therewith, such as treating or preventing Parkinson's disease or symptoms or physiology associated therewith such as motor deficits or nigrostriatal degeneration; or, for inducing nigrostriatal regeneration. Advantageously, the methods involve administering a lentiviral vector that expresses GDNF, such as human GDNF, or a variant, homolog, analog or derivative thereof.

Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases

Growing community of inventors

Oxford, United Kingdom

Stuart Naylor